| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2007-0039
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2007-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B90-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2016-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-108430579-B |
| titleOfInvention |
A system for treating brain tumors by using an ultrasound system |
| abstract |
The present invention provides a method of reducing the effective amount of bevacizumab required to treat brain tumors. The present invention also provides a kit for use in the method. The method employs a combined strategy of combining bevacizumab treatment with ultrasound irradiation, comprising at least the steps of: administering bevacizumab to a subject; administering an ultrasound-responsive medium to the subject; and administering to the subject Ultrasound irradiation. Specific effective doses of bevacizumab treatment and ultrasound irradiation were determined. The efficacy of conventional bevacizumab therapy was significantly improved. |
| priorityDate |
2015-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |